Kwaloz D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed to provide effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility by enhancing the movement of stomach contents into the intestines, thereby alleviating symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting healing of acid-related mucosal damage and providing symptomatic relief in conditions like gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. The sustained-release (SR) formulation ensures prolonged therapeutic plasma levels, enhancing efficacy and improving patient compliance through reduced dosing frequency. Kwaloz D Capsule SR is indicated for the treatment of acid peptic disorders accompanied by delayed gastric emptying, including GERD with associated dyspepsia and gastroparesis. It is contraindicated in patients with known hypersensitivity to any component, prolactinoma, or gastrointestinal hemorrhage. Caution is advised in patients with hepatic or renal impairment. Common adverse effects may include headache, dry mouth, abdominal cramps, and diarrhea. Clinical monitoring is recommended to assess therapeutic response and detect potential side effects.